--- title: "Arcadia Biosciences | 8-K: FY2026 Q1 Revenue: USD 1.1 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286461084.md" datetime: "2026-05-14T20:15:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286461084.md) - [en](https://longbridge.com/en/news/286461084.md) - [zh-HK](https://longbridge.com/zh-HK/news/286461084.md) --- # Arcadia Biosciences | 8-K: FY2026 Q1 Revenue: USD 1.1 M Revenue: As of FY2026 Q1, the actual value is USD 1.1 M. EPS: As of FY2026 Q1, the actual value is USD -2.11. #### Overall Financial Performance Arcadia Biosciences, Inc. reported a net loss attributable to common stockholders of - $4.4 million, or - $2.11 per share, for the first quarter of 2026, which is a - $7.0 million decrease from the $2.6 million net income, or $1.90 per share, recorded in the first quarter of 2025. The net loss attributable to common stockholders was -$4,385 thousand for the three months ended March 31, 2026, compared to $2,599 thousand for the same period in 2025. Loss from continuing operations was -$779 thousand for the first quarter of 2026, compared to an income of $530 thousand for the same period in 2025, representing a - $1,309 thousand, or -247%, change. The net loss from continuing operations was -$4,385 thousand for the three months ended March 31, 2026, compared to a net income of $2,599 thousand for the three months ended March 31, 2025. #### Revenue Total revenues were $1,100 thousand for the first quarter of 2026, a decrease of - $100 thousand, or -8%, compared to $1,200 thousand in the first quarter of 2025. This decrease was primarily due to a revenue reserve release of approximately $193,000 in 2025. Zola® coconut water revenues and unit volumes increased at a double-digit rate year-over-year, with unit volumes specifically increasing by 18%. The Zola coconut water sales also benefited from a price increase implemented at the beginning of the year. #### Operating Expenses Total operating expenses increased by - $1,209 thousand, or -180%, to $1,879 thousand in the first quarter of 2026 from $670 thousand in the first quarter of 2025. Cost of revenues increased by $18,000, or 3%, to $700 thousand in the first quarter of 2026 from $682 thousand in the first quarter of 2025, driven mainly by the increase in Zola sales volume, which led to higher product costs and freight expenses. Selling, general, and administrative (SG&A) expenses decreased by $559,000 to $1,179 thousand in the first quarter of 2026 compared to $1,738 thousand for the same period in 2025, primarily due to the absence of M&A fees and lower employee costs. SG&A expenses reached their lowest level in Arcadia Biosciences, Inc.’s history as a public company. #### Other Financial Metrics The decrease in net income was primarily driven by a - $2.9 million loss relating to the January 2026 warrant inducement offer transaction and an additional - $1.5 million in other losses. The loss on January 2026 inducement offer was -$2,877 thousand for the three months ended March 31, 2026. Other loss, net, was -$1,504 thousand for the three months ended March 31, 2026. The decrease also included the absence of a $750,000 gain on the sale of patent portfolios and a $1.0 million gain related to the change in fair value of contingent consideration liability recognized in the first quarter of 2025. The company brought in gross proceeds of approximately $2.1 million from the exercise of previously outstanding preferred investment options. Interest income was $5 thousand for the three months ended March 31, 2026, compared to $207 thousand for the same period in 2025. The change in fair value of common stock warrant and option liabilities was $1,191 thousand for the three months ended March 31, 2026, compared to $1,862 thousand for the same period in 2025. Issuance and offering costs were -$421 thousand for the three months ended March 31, 2026. #### Cash Flow Net cash used in operating activities was -$1,099 thousand for the three months ended March 31, 2026, an improvement from -$1,588 thousand for the same period in 2025. Net cash provided by investing activities was $0 thousand for the three months ended March 31, 2026, compared to $500 thousand for the same period in 2025. Net cash provided by financing activities was $1,794 thousand for the three months ended March 31, 2026, significantly up from $5 thousand for the same period in 2025. The net increase in cash and cash equivalents was $695 thousand for the three months ended March 31, 2026, compared to a net decrease of -$1,083 thousand for the same period in 2025. Cash and cash equivalents at the end of the period were $954 thousand as of March 31, 2026, compared to $3,159 thousand as of March 31, 2025. #### Balance Sheet Highlights Cash and cash equivalents were $954 thousand as of March 31, 2026, compared to $259 thousand as of December 31, 2025. Short-term investments were $2,766 thousand as of March 31, 2026, down from $4,304 thousand as of December 31, 2025. Total current assets were $5,169 thousand as of March 31, 2026, compared to $6,356 thousand as of December 31, 2025. Total assets were $5,323 thousand as of March 31, 2026, compared to $6,546 thousand as of December 31, 2025. Total current liabilities were $1,365 thousand as of March 31, 2026, compared to $2,059 thousand as of December 31, 2025. Total liabilities were $2,438 thousand as of March 31, 2026, compared to $2,406 thousand as of December 31, 2025. The accumulated deficit was -$285,602 thousand as of March 31, 2026, compared to -$281,217 thousand as of December 31, 2025. Total stockholders’ equity was $2,885 thousand as of March 31, 2026, compared to $4,140 thousand as of December 31, 2025. #### Outlook / Guidance Arcadia Biosciences, Inc. continues to evaluate strategic alternatives while remaining focused on growing its Zola coconut water brand. The company anticipates launching a new product this fall, which is expected to be available on the shelves of many of its largest customers. ### Related Stocks - [RKDA.US](https://longbridge.com/en/quote/RKDA.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [The Seed 100: The best early-stage investors of 2026](https://longbridge.com/en/news/286743225.md) - [INTOUCH INSIGHT ANNOUNCES Q1 2026 FINANCIAL RESULTS](https://longbridge.com/en/news/287124506.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)